GlassScriptPhysician profile
Stephen L Kindred
NPI 1720065584
$17,276.86
in general payments reported to CMS, 2019-2025
54 companies · $3,540 in 2025
The $3,540 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,030 · 2020: $1,219 · 2021: $1,937 · 2022: $2,323 · 2023: $2,818 · 2024: $3,410 · 2025: $3,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,763 · Education: $4.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,762.79 |
| Education | $4.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,226.78 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,506.99 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,434.74 | 2019-2025 | |
| Lilly USA, LLC | $1,288.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,098.30 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $923.46 | 2019-2022 | |
| Glaxosmithkline, LLC. | $855.73 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $672.84 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $651.59 | 2022-2025 | |
| Dexcom, INC. | $507.65 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Boston Scientific Corporation | $434.36 | 2024-2025 | Watchman Access System |
| Amgen INC. | $415.96 | 2019-2025 | Repatha, Evenity, Repatha |
| Merck Sharp & Dohme LLC | $415.01 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Kowa Pharmaceuticals America, INC. | $407.75 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Phathom Pharmaceuticals, INC. | $366.21 | 2023-2024 | Voquezna |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kindred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.